Vaxxinity's covid-19 vaccine candidate ub-612 produces high levels of neutralizing antibodies against omicron and other variants of concern

Dallas, feb. 11, 2022 (globe newswire) -- vaxxinity, inc. (nasdaq: vaxx), a u.s. company pioneering the development of a new class of immunotherapeutic vaccines, today announced results from studies demonstrating the ability of ub-612, its covid-19 vaccine candidate, to elicit a broad immune response against multiple variants of concern, and specifically more than three-times higher titers of neutralizing antibodies against the omicron variant of sars-cov-2 than an approved mrna vaccine with boosters.
VAXX Ratings Summary
VAXX Quant Ranking